Protein Allostery in Rational Drug Design

被引:8
|
作者
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, Sakai, Osaka, Japan
来源
关键词
Protein kinase; Allosteric inhibitor; Structure-based drug discovery; High selectivity; CRYSTAL-STRUCTURES; KINASE INHIBITORS; BINDING; IDENTIFICATION; TARGET; POTENT; SITE; SELECTIVITY; MECHANISM; CK2-ALPHA;
D O I
10.1007/978-981-13-8719-7_3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This chapter focuses on protein kinases that transfer the phosphate group of ATP to the hydroxyl group of a substrate protein. Five hundred eighteen human protein kinases are classified into serine/threonine kinases and tyrosine kinases and individually or synergistically transduce physiologic stimuli into cell to promote cell proliferation or apoptosis, etc. Protein kinases are identified as drug targets because dysfunction of kinases leads to severe diseases such as cancers and autoimmune diseases. A large number of the crystal structures of the protein kinase inhibitor complex are available in Protein Data Bank and facilitated the drug discovery targeting protein kinases. The protein kinase inhibitors are classified into categories, Type-I, Type-II, Type-III, Type-IV, and Type-V, and as a separate class, covalent-type inhibitors. In any type, a protein kinase inhibitor bound to the allosteric region is advantageous in terms of selectivity compared to the traditional ATP-competitive one. In the following sections, the successful and promising examples of the partially or fully allosteric protein kinase inhibitors are illustrated in the following pages.
引用
收藏
页码:45 / 64
页数:20
相关论文
共 50 条
  • [21] PROTEIN CRYSTALLOGRAPHY AND COMPUTER-GRAPHICS TOWARD RATIONAL DRUG DESIGN
    HOL, WGJ
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1986, 25 (09): : 767 - 778
  • [22] Design of protein switches based on an ensemble model of allostery
    Choi, Jay H.
    Laurent, Abigail H.
    Hilser, Vincent J.
    Ostermeier, Marc
    NATURE COMMUNICATIONS, 2015, 6
  • [23] Advances in Rational Drug Design
    Reddy, M. Rami
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (26) : 4673 - 4673
  • [24] Multiscale Allostery: Basic Mechanisms and Versatility in Diagnostics and Drug Design
    Berezovsky, Igor N.
    Nussinov, Ruth
    JOURNAL OF MOLECULAR BIOLOGY, 2022, 434 (17)
  • [25] Overview of rational drug design
    Reddy, M. Rami
    Parrill, Abby L.
    ACS Symposium Series, 1999, 719 : 1 - 11
  • [26] Strategies in the Rational Drug Design
    Mavromoustakos, T.
    Durdagi, S.
    Koukoulitsa, C.
    Simcic, M.
    Papadopoulos, M. G.
    Hodoscek, M.
    Grdadolnik, S. Golic
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (17) : 2517 - 2530
  • [27] RATIONAL DRUG DESIGN IN PARASITOLOGY
    DOUGLAS, KT
    PARASITOLOGY TODAY, 1994, 10 (10): : 389 - 392
  • [28] Protein Allostery
    Ando, N.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2020, 76 : A230 - A230
  • [29] Allostery in Drug Development
    Cheng, Xi
    Jiang, Hualiang
    PROTEIN ALLOSTERY IN DRUG DISCOVERY, 2019, 1163 : 1 - 23
  • [30] Allostery in drug development
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 10 - 10